You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 109 No. 7, July 1991 TABLE OF CONTENTS
  Archives
  •  Online Features
  CORRESPONDENCE
 This Article
 •References
 •Full text PDF
 • Reply to article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Axonal Transport and Anterior Ischemic Optic Neuropathy-Reply

Robert C. Sergott, MD; Thomas M. Bosley, MD; Marc S. Cohen, MD; Peter J. Savino, MD
Philadelphia, Pa

Arch Ophthalmol. 1991;109(7):916-917.

Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

In Reply.

—First, we believe that optic nerve sheath decompression does improve the visual function of approximately 75% of patients with the progressive form of nonarteritic ischemic optic neuropathy. At present, we believe that optic nerve sheath decompression in some way improves the hemodynamic perfusion of the optic nerve, and possibly the optic disc.

We agree that the issue of axoplasmic transport is complex and confusing. Although axoplasmic transport may not be directly responsible for visual function and neural conduction, we doubt that the physiologic processes of axoplasmic transport and impulse conduction can be segregated irrevocably in specific pathologic situations. For example, the experiments of McLeod et al1 dividing the posterior ciliary arteries of monkey eyes to produce ischemic optic neuropathy demonstrated an obstruction of axoplasmic transport at the lamina cribrosa.

Finally, the need for a multicenter clinical trial depends on the acceptance or rejection by the neuro-ophthalmic . . . [Full Text PDF of this Article]



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1991 American Medical Association. All Rights Reserved.